Please assess the completion status of the following clinical trial:

Trial Title: VA NEPHRON-D: Diabetes iN Nephropathy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Albuminuria \>300mg/gram creatinine~* Stage 2 or 3 CKD (eGFR 30 to \<90 mg/min/1.73m\*2 )~* Able to give informed consent~* Telephone contact available~Exclusion Criteria:~* History of intolerance to ACEI or ARB~* Serum potassium level \>5.5 meq/L~* Receiving sodium polystyrene sulfonate (Kayexalate)~* Pregnancy, breast feeding, planning to become pregnant or sexually active and not using birth control~* Renal transplant recipient~* Suspected non-diabetic kidney disease~* Inability to discontinue current use of ACEI/ARB combination~* Current use of Lithium~* Severe (end-stage) comorbid disease~* Prisoner~* Age \<18~* Estimated glomerular filtration rate (GFR) \<30 or \>=90 ml/min/1.73m\*m~* HbA1c \>10.5%~* Patient refusal~* Participation in a concurrent interventional study~* Blood pressure \>180/95~* Unwilling to stop any proscribed medications after enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination of ARB and ACEI (Type: EXPERIMENTAL): Combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB)
- Monotherapy ARB (Type: ACTIVE_COMPARATOR): Mono therapy arm. Standard treatment with angiotensin receptor blocker (ARB)

Based on this trial design, predict the completion outcome and termination type (if applicable).